Global Specialty Generics Market to Reach $207.4 Billion by 2027

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 8. - Influencer Pool: 1244. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 18, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Specialty Generics Industry" - https://www.reportlinker.com/p06032966/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

• Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

• Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

• Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

• Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

• Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Specialty Generics Market to Reach $207.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Specialty Generics estimated at US$63.5 Billion in the year 2020, is projected to reach a revised size of US$207.4 Billion by 2027, growing at aCAGR of 18.4% over the period 2020-2027. Injectables, one of the segments analyzed in the report, is projected to record 19.6% CAGR and reach US$149.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Other Types segment is readjusted to a revised 15.7% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 18% CAGR
- The Specialty Generics market in the U.S. is estimated at US$18.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$36.4 Billion by the year 2027 trailing a CAGR of 18% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.5% and 15.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR.

Select Competitors (Total 43 Featured) -

• Akorn Inc.

• Apotex Corp.

• Endo International plc.

• Mallinckrodt

• Mylan N.V.

• Pfizer Inc.

• Sandoz International GmbH

• Sun Pharmaceutical Industries Ltd.

• Teva Pharmaceuticals Industries

• Valeant Pharmaceuticals

Read the full report: https://www.reportlinker.com/p06032966/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Specialty Generics Competitor Market Share Scenario Worldwide
(in %): 2020E
Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Specialty Generics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 2: World Historic Review for Specialty Generics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Specialty Generics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Injectables by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 5: World Historic Review for Injectables by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Injectables by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Other Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 8: World Historic Review for Other Types by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Other Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 11: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 13: World Current & Future Analysis for Inflammatory
Conditions by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 14: World Historic Review for Inflammatory Conditions by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Inflammatory Conditions
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Multiple
Sclerosis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 17: World Historic Review for Multiple Sclerosis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Multiple Sclerosis by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Hepatitis C by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 20: World Historic Review for Hepatitis C by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Hepatitis C by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 23: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
Market Analytics
Table 25: USA Current & Future Analysis for Specialty Generics
by Type - Injectables and Other Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 26: USA Historic Review for Specialty Generics by Type -
Injectables and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 27: USA 15-Year Perspective for Specialty Generics by
Type - Percentage Breakdown of Value Sales for Injectables and
Other Types for the Years 2012, 2020 & 2027

Table 28: USA Current & Future Analysis for Specialty Generics
by Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 29: USA Historic Review for Specialty Generics by
Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Specialty Generics by
Application - Percentage Breakdown of Value Sales for Oncology,
Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and
Other Applications for the Years 2012, 2020 & 2027

CANADA
Table 31: Canada Current & Future Analysis for Specialty
Generics by Type - Injectables and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 32: Canada Historic Review for Specialty Generics by Type -
Injectables and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 33: Canada 15-Year Perspective for Specialty Generics by
Type - Percentage Breakdown of Value Sales for Injectables and
Other Types for the Years 2012, 2020 & 2027

Table 34: Canada Current & Future Analysis for Specialty
Generics by Application - Oncology, Inflammatory Conditions,
Multiple Sclerosis, Hepatitis C and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 35: Canada Historic Review for Specialty Generics by
Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: Canada 15-Year Perspective for Specialty Generics by
Application - Percentage Breakdown of Value Sales for Oncology,
Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and
Other Applications for the Years 2012, 2020 & 2027

JAPAN
Table 37: Japan Current & Future Analysis for Specialty
Generics by Type - Injectables and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 38: Japan Historic Review for Specialty Generics by Type -
Injectables and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 39: Japan 15-Year Perspective for Specialty Generics by
Type - Percentage Breakdown of Value Sales for Injectables and
Other Types for the Years 2012, 2020 & 2027

Table 40: Japan Current & Future Analysis for Specialty
Generics by Application - Oncology, Inflammatory Conditions,
Multiple Sclerosis, Hepatitis C and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: Japan Historic Review for Specialty Generics by
Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: Japan 15-Year Perspective for Specialty Generics by
Application - Percentage Breakdown of Value Sales for Oncology,
Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and
Other Applications for the Years 2012, 2020 & 2027

CHINA
Table 43: China Current & Future Analysis for Specialty
Generics by Type - Injectables and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 44: China Historic Review for Specialty Generics by Type -
Injectables and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 45: China 15-Year Perspective for Specialty Generics by
Type - Percentage Breakdown of Value Sales for Injectables and
Other Types for the Years 2012, 2020 & 2027

Table 46: China Current & Future Analysis for Specialty
Generics by Application - Oncology, Inflammatory Conditions,
Multiple Sclerosis, Hepatitis C and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 47: China Historic Review for Specialty Generics by
Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 48: China 15-Year Perspective for Specialty Generics by
Application - Percentage Breakdown of Value Sales for Oncology,
Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and
Other Applications for the Years 2012, 2020 & 2027

EUROPE
Market Facts & Figures
Market Analytics
Table 49: Europe Current & Future Analysis for Specialty
Generics by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2020 through 2027 and % CAGR

Table 50: Europe Historic Review for Specialty Generics by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 51: Europe 15-Year Perspective for Specialty Generics by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027

Table 52: Europe Current & Future Analysis for Specialty
Generics by Type - Injectables and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 53: Europe Historic Review for Specialty Generics by Type -
Injectables and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 54: Europe 15-Year Perspective for Specialty Generics by
Type - Percentage Breakdown of Value Sales for Injectables and
Other Types for the Years 2012, 2020 & 2027

Table 55: Europe Current & Future Analysis for Specialty
Generics by Application - Oncology, Inflammatory Conditions,
Multiple Sclerosis, Hepatitis C and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 56: Europe Historic Review for Specialty Generics by
Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: Europe 15-Year Perspective for Specialty Generics by
Application - Percentage Breakdown of Value Sales for Oncology,
Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and
Other Applications for the Years 2012, 2020 & 2027

FRANCE
Table 58: France Current & Future Analysis for Specialty
Generics by Type - Injectables and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 59: France Historic Review for Specialty Generics by Type -
Injectables and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 60: France 15-Year Perspective for Specialty Generics by
Type - Percentage Breakdown of Value Sales for Injectables and
Other Types for the Years 2012, 2020 & 2027

Table 61: France Current & Future Analysis for Specialty
Generics by Application - Oncology, Inflammatory Conditions,
Multiple Sclerosis, Hepatitis C and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 62: France Historic Review for Specialty Generics by
Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 63: France 15-Year Perspective for Specialty Generics by
Application - Percentage Breakdown of Value Sales for Oncology,
Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and
Other Applications for the Years 2012, 2020 & 2027

GERMANY
Table 64: Germany Current & Future Analysis for Specialty
Generics by Type - Injectables and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 65: Germany Historic Review for Specialty Generics by
Type - Injectables and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 66: Germany 15-Year Perspective for Specialty Generics by
Type - Percentage Breakdown of Value Sales for Injectables and
Other Types for the Years 2012, 2020 & 2027

Table 67: Germany Current & Future Analysis for Specialty
Generics by Application - Oncology, Inflammatory Conditions,
Multiple Sclerosis, Hepatitis C and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Germany Historic Review for Specialty Generics by
Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 69: Germany 15-Year Perspective for Specialty Generics by
Application - Percentage Breakdown of Value Sales for Oncology,
Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and
Other Applications for the Years 2012, 2020 & 2027

ITALY
Table 70: Italy Current & Future Analysis for Specialty
Generics by Type - Injectables and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 71: Italy Historic Review for Specialty Generics by Type -
Injectables and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 72: Italy 15-Year Perspective for Specialty Generics by
Type - Percentage Breakdown of Value Sales for Injectables and
Other Types for the Years 2012, 2020 & 2027

Table 73: Italy Current & Future Analysis for Specialty
Generics by Application - Oncology, Inflammatory Conditions,
Multiple Sclerosis, Hepatitis C and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 74: Italy Historic Review for Specialty Generics by
Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 75: Italy 15-Year Perspective for Specialty Generics by
Application - Percentage Breakdown of Value Sales for Oncology,
Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and
Other Applications for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 76: UK Current & Future Analysis for Specialty Generics
by Type - Injectables and Other Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 77: UK Historic Review for Specialty Generics by Type -
Injectables and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 78: UK 15-Year Perspective for Specialty Generics by Type -
Percentage Breakdown of Value Sales for Injectables and Other
Types for the Years 2012, 2020 & 2027

Table 79: UK Current & Future Analysis for Specialty Generics
by Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 80: UK Historic Review for Specialty Generics by
Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 81: UK 15-Year Perspective for Specialty Generics by
Application - Percentage Breakdown of Value Sales for Oncology,
Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and
Other Applications for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 82: Rest of Europe Current & Future Analysis for
Specialty Generics by Type - Injectables and Other Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 83: Rest of Europe Historic Review for Specialty Generics
by Type - Injectables and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 84: Rest of Europe 15-Year Perspective for Specialty
Generics by Type - Percentage Breakdown of Value Sales for
Injectables and Other Types for the Years 2012, 2020 & 2027

Table 85: Rest of Europe Current & Future Analysis for
Specialty Generics by Application - Oncology, Inflammatory
Conditions, Multiple Sclerosis, Hepatitis C and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: Rest of Europe Historic Review for Specialty Generics
by Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 87: Rest of Europe 15-Year Perspective for Specialty
Generics by Application - Percentage Breakdown of Value Sales
for Oncology, Inflammatory Conditions, Multiple Sclerosis,
Hepatitis C and Other Applications for the Years 2012, 2020 &
2027

ASIA-PACIFIC
Table 88: Asia-Pacific Current & Future Analysis for Specialty
Generics by Type - Injectables and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 89: Asia-Pacific Historic Review for Specialty Generics
by Type - Injectables and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 90: Asia-Pacific 15-Year Perspective for Specialty
Generics by Type - Percentage Breakdown of Value Sales for
Injectables and Other Types for the Years 2012, 2020 & 2027

Table 91: Asia-Pacific Current & Future Analysis for Specialty
Generics by Application - Oncology, Inflammatory Conditions,
Multiple Sclerosis, Hepatitis C and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 92: Asia-Pacific Historic Review for Specialty Generics
by Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 93: Asia-Pacific 15-Year Perspective for Specialty
Generics by Application - Percentage Breakdown of Value Sales
for Oncology, Inflammatory Conditions, Multiple Sclerosis,
Hepatitis C and Other Applications for the Years 2012, 2020 &
2027

REST OF WORLD
Table 94: Rest of World Current & Future Analysis for Specialty
Generics by Type - Injectables and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 95: Rest of World Historic Review for Specialty Generics
by Type - Injectables and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 96: Rest of World 15-Year Perspective for Specialty
Generics by Type - Percentage Breakdown of Value Sales for
Injectables and Other Types for the Years 2012, 2020 & 2027

Table 97: Rest of World Current & Future Analysis for Specialty
Generics by Application - Oncology, Inflammatory Conditions,
Multiple Sclerosis, Hepatitis C and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: Rest of World Historic Review for Specialty Generics
by Application - Oncology, Inflammatory Conditions, Multiple
Sclerosis, Hepatitis C and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 99: Rest of World 15-Year Perspective for Specialty
Generics by Application - Percentage Breakdown of Value Sales
for Oncology, Inflammatory Conditions, Multiple Sclerosis,
Hepatitis C and Other Applications for the Years 2012, 2020 &
2027

IV. COMPETITION

Total Companies Profiled: 43
Read the full report: https://www.reportlinker.com/p06032966/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001